Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

491 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
NT-702 (parogrelil hydrochloride, NM-702), a novel and potent phosphodiesterase inhibitor, improves reduced walking distance and lowered hindlimb plantar surface temperature in a rat experimental intermittent claudication model.
Ishiwata N, Noguchi K, Kawanishi M, Asakura Y, Hori M, Mitani A, Ito Y, Takahashi K, Nishiyama H, Shudo N, Takahashi S, Takahashi K, Tsuruzoe N, Nakaike S. Ishiwata N, et al. Among authors: kawanishi m. Life Sci. 2007 Sep 1;81(12):970-8. doi: 10.1016/j.lfs.2007.07.025. Epub 2007 Aug 8. Life Sci. 2007. PMID: 17850826
NT-702 (parogrelil hydrochloride, NM-702), a novel and potent phosphodiesterase 3 inhibitor, suppress the asthmatic response in guinea pigs, with both bronchodilating and anti-inflammatory effects.
Hori M, Iwama T, Asakura Y, Kawanishi M, Kamon J, Hoshino A, Takahashi S, Takahashi K, Nakaike S, Tsuruzoe N. Hori M, et al. Among authors: kawanishi m. Eur J Pharmacol. 2009 Sep 15;618(1-3):63-9. doi: 10.1016/j.ejphar.2009.07.005. Epub 2009 Jul 17. Eur J Pharmacol. 2009. PMID: 19616537
Efficacy and safety of anti-TNF multivalent NANOBODY® compound 'ozoralizumab' without methotrexate co-administration in patients with active rheumatoid arthritis: A 52-week result of phase III, randomised, open-label trial (NATSUZORA trial).
Tanaka Y, Kawanishi M, Nakanishi M, Yamasaki H, Takeuchi T. Tanaka Y, et al. Among authors: kawanishi m. Mod Rheumatol. 2023 Aug 25;33(5):875-882. doi: 10.1093/mr/roac126. Mod Rheumatol. 2023. PMID: 36201360 Clinical Trial.
Antimicrobial Use in the Animal Sector in Japan from 2011 to 2022.
Hosoi Y, Matsuda M, Kawanishi M, Harada S, Kumakawa M, Sekiguchi H, Asai T, Sekiya T. Hosoi Y, et al. Among authors: kawanishi m. Antibiotics (Basel). 2024 Dec 10;13(12):1204. doi: 10.3390/antibiotics13121204. Antibiotics (Basel). 2024. PMID: 39766594 Free PMC article.
C5 palsy following one- or two-level anterior cervical discectomy and fusion: Incidence and neurological recovery in a retrospective neurosurgical multicenter study.
Fujikawa Y, Ikeda N, Sakai K, Yagi R, Hiramatsu R, Kameda M, Nonoguchi N, Furuse M, Kawabata S, Yokoyama K, Kawanishi M, Fujishiro T, Park Y, Tanabe H, Takami T, Wanibuchi M. Fujikawa Y, et al. Among authors: kawanishi m. J Clin Neurosci. 2024 Dec 24;132:111000. doi: 10.1016/j.jocn.2024.111000. Online ahead of print. J Clin Neurosci. 2024. PMID: 39721117
491 results